DMHCA (N,N-dimethyl-3β-hydroxycholenamide, Figure 1) is a gene-selectiveLXR modulator that mediates potent transcriptional activation of ABCA1and ApoE gene expression, while minimally affecting SREBP-1c.22,23 Thus, it represents an excellent therapeutic candidate for AD, circumventingthe side effects of alternative LXRs agonists. The gene discussed is APOE; the disease is Alzheimer disease.